Matica Biotechnology
Private Company
Funding information not available
Overview
Matica Biotechnology, founded in 2015 and headquartered in College Station, Texas, is a specialized viral vector and gene therapy CDMO. It offers a full suite of services including cell line development, process and assay development, and GMP production, supported by its proprietary MatiMax™ platform and single-use technologies. The company has a global footprint with five sites and a track record of over 300 vector projects, positioning it as a key manufacturing partner for biotech firms advancing cell and gene therapies.
Technology Platform
MatiMax™ proprietary cell line platform for viral vector production, combined with advanced single-use bioprocessing equipment and in-line analytics.
Opportunities
Risk Factors
Competitive Landscape
Matica competes in the specialized viral vector CDMO space against large, established players like Lonza and Catalent, as well as other focused competitors such as Oxford Biomedica, Genezen, and Vigene Biosciences. Differentiation is achieved through proprietary technology (MatiMax™), a purpose-built facility, and a client-centric service model emphasizing speed and quality.